Home » Blog » Drug Pricing, MACRA Exemptions, Healthcare Exchange Profitability, and Artificial Intelligence in Healthcare

Drug Pricing, MACRA Exemptions, Healthcare Exchange Profitability, and Artificial Intelligence in Healthcare


IP Blog | Dave Melin | July 2, 2017

BioBlog Weekly oncologyIn this week’s BioBlog we look at the latest developments in the ongoing drug pricing battle, another group of providers receiving exemption from the MACRA requirements, and look into the future of using artificial intelligence in healthcare.

Draft Order on Drug Prices Proposes Easing Regulations

The New York Times reports that a draft of an executive order Trump plans to issue would ease regulations on pharmaceutical companies, with hopes it would help drive down drug prices.

Worldwide Drug Sale Forecasts Fall as Pricing Pressures Mount

For the first time in over a decade, pharmaceutical sales are expected to drop due to the continued battle over high drug prices.

CMS Proposal Exempts Another 134K from MACRA

Recently CMS informed another 134,000 small providers that they will not be required to meet the MACRA requirements.

Eye on the Exchanges: What Predictive Analytics Tells Us About Drivers of Health Plan Profitability

This article examines what allows some insurers to remain profitable on the plans they offer on the healthcare exchanges, while others keep losing millions.

84% of Execs: Artificial Intelligence Will Transform Healthcare

According to this report many healthcare executives believe artificial intelligence will play a major role in the interaction of patients in the future, by changing how they are able to obtain information from the patients.

 


Topics in this Post:



Leave a Comment

Your email address will not be published. Required fields are marked *